15 Countries Where Tilray Brands Is Capturing Market Share…

Although the last year has been a volatile period for Tilray Brands Inc. (Nasdaq: TLRY) (TSX: TLRY), the leading Canadian Licensed Producer (LP) has been executing on a global expansion strategy and is selling cannabis in new markets all over the world.

According to the most recent press release, Tilray Brands is selling a comprehensive portfolio of THC and CBD products in 22 countries. Today, we covered 15 countries that Tilray Brands is levered to and believe our readers should be aware of the scale of its international business.

1. The United States – Last year, Tilray Brands acquired Aphria and the transaction included strategic US assets. Before being acquired, Aphria acquired a well-known craft brewer and we expect the asset to play an important role with how it capitalizes on the US. Last year, the company acquired the majority of MedMen’s amended convertible notes and we considered this transaction to be strategic for the long-term opportunity.
2. Canada – During the summer, Tilray Brands acquired a secured convertible note issued to HT Investments by HEXO. The transaction is expected to benefit Tilray in many ways, including substantial cost-saving synergies, increased strength in product innovation, and the ability to capitalize on Canada and high-profile international markets
3. Germany – By acquiring Aphria, Tilray Brands enhanced its leverage to the German cannabis market and we are bullish on the market. In early September, Tilray initiated a discussion with German regulators on recreational cannabis legalization and we expect the business to be a beneficiary of the growth of the market. Tilray operates a GMP-certified cannabis cultivation facility in Germany.
4. Italy – Last week, Tilray Medical was approved to start importing and distributing its medical cannabis oral solution in Italy. We believe the country’s cannabis industry is barely in the first inning of a growth cycle. We are favorable on how Tilray Medical has an established a national pharmaceutical distribution network to distribute its oral solution across the country
5. Portugal – During the first calendar quarter of 2021, Tilray Portugal was approved to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the 17th country to receive Tilray medical cannabis in the world (as of February 4, 2021). Since then, the facility in Portugal has supplied medical cannabis to several markets in the EU and we are bullish on this aspect of the business
6. United Kingdom – Last year, Tilray entered into an agreement with Grow Pharma to import and distribute branded medical cannabis products into the UK. The following year, Tilray Brands launched POLLEN, a CBD lifestyle brand with a new approach to wellness, on Amazon UK and we will monitor how the country starts to impact revenue growth.
7. New Zealand – In September, Tilray’s medical cannabis division received approval from the Natural Health Science Foundation (NHSF) for the use of its flagship product, Tilray Purified Oral Solution CBD100, in clinical trials in New Zealand. Earlier this year, the cannabis company started to offer an online medical cannabis education platform for healthcare workers in the country and we are favorable on the management team’s commitment to education
8. Australia – In late January, Tilray Brands announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for healthcare providers. The company is also conducting clinical trials on its Purified Oral Solution CBD100 in Australia
9. Poland – in mid-August, Tilray Brands received approval to commercialize branded medical cannabis products in Poland which further expands its product offering and distribution across pharmacies in Europe. Tilray operates a GMP-certified cannabis cultivation facility in Portugal.
10. Spain – In early 2021, Tilray started to sell medical cannabis to patients in Spain. The company shipped cannabis from its GMP production facility in Portugal to Spain and we are bullish on the long-term opportunity in the market.
11. France – In January 2021, the cannabis company was selected by a French national agency to supply GMP certified medical cannabis products for experimentation in France. Tilray will supply products to serve patients for the duration of the experiment which is expected to take between 18 and 24 months.
12. Israel – Prior to the start of the COVID pandemic, Tilray Brands entered into a strategic agreement with Canndoc Ltd., a wholly-owned subsidiary of InterCure Ltd. (TASE: INCR), to export medical cannabis to Israel.
13. Switzerland – In late 2019, Tilray exported medical cannabis extracts to Switzerland. Part of its strategy to capitalize on the market, has been its plan to offer patients an assortment of products to meet their varying medical indications.
14. Luxembourg – in October 2021, Luxembourg’s Ministry of Health selected Tilray to provide GMP certified medical cannabis to the country’s medical cannabis program.
15. Malta – During the first calendar quarter of 2022, Tilray Medical expanded its medical cannabis offering and launched the first EU GMP medical cannabis oil products in Malta.

If you are interested in learning about Tilray’s leverage to the global cannabis market, please send an email to support@technical420.com with the subject “Tilray Brands” to be added to our distribution list.

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories